



Neuland

Experience. Insight. Vision.

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2013

PART - I

Amount in ₹ Million

Sl. No.	Particulars	Quarter Ended 31.12.2013 (Unaudited)	Quarter Ended 30.09.2013 (Unaudited)	Quarter Ended 31.12.2012 (Unaudited)	Nine Months Ended 31.12.2013 (Unaudited)	Nine Months Ended 31.12.2012 (Unaudited)	Year Ended 31.03.2013 (Audited)
1	Income from Operations						
	(a) Net Sales / Income from Operations						
	Exports	934.02	815.24	844.64	2,683.94	2,627.11	3,323.09
	Domestic	374.26	227.61	220.80	880.37	882.60	1,282.77
	Total	1,308.28	1,042.85	1,065.44	3,564.31	3,509.71	4,605.86
	(b) Other Operating Income	7.20	8.12	8.59	22.53	24.77	33.18
	Total Income from Operations (Net)	1,315.48	1,050.97	1,074.03	3,586.84	3,534.48	4,639.04
2	Expenses						
	(a) Consumption of Raw Materials	648.41	582.11	612.14	1,865.81	2,127.17	2,726.06
	(b) Changes in inventories of finished goods and work in process	31.37	(41.79)	(32.88)	36.15	(60.76)	(34.50)
	(c) Employee Benefit Expense	82.79	89.15	80.54	268.29	251.55	348.83
	(d) Depreciation	36.75	37.10	36.96	110.37	110.57	146.22
	(e) Manufacturing Expenses	137.01	116.58	113.28	352.95	333.41	458.45
	(f) Other Expenses	222.58	142.07	111.74	479.24	360.42	493.29
	Total Expenses	1,158.91	925.22	921.78	3,112.81	3,122.36	4,138.35
3	Profit from Operations before Foreign Exchange (gain) / loss and Finance Costs (1-2)	156.57	125.75	152.25	474.03	412.12	500.69
4	Foreign Exchange (gain) / loss (Net)	0.13	15.98	12.65	38.34	37.17	32.46
5	Profit from Operations before Finance Costs (3-4)	156.44	109.77	139.60	435.69	374.95	468.23
6	Finance Costs	59.52	63.06	90.19	181.59	248.36	313.30
7	Profit / (Loss) before Tax (5-6)	96.92	46.71	49.41	254.10	126.59	154.93
8	Tax Expense						
	(a) Current tax	20.79	10.77	8.83	52.61	24.35	30.19
	(b) Deferred Tax	28.69	12.28	7.85	73.33	7.85	41.87
	(c) MAT Credit entitlement	(20.79)	(10.77)	-	(52.61)	-	(53.50)
9	Net Profit / (Loss) for the period (7-8)	68.23	34.43	32.73	180.77	94.39	136.37
10	Paid-up Equity Share Capital (Face Value ₹10 per share)	77.16	77.16	77.16	77.16	77.16	77.16
11	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						898.33
12	Earnings per Share (EPS) (in ₹)						
	(a) Basic	8.92	4.50	4.28	23.65	12.35	17.84
	(b) Diluted	8.92	4.50	4.28	23.63	12.34	17.82

Neuland Laboratories Limited

Registered Office: Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113, Road no: 2, Banjara hills, Hyderabad - 500 034. AP, India. Tel : +91-40-30211600 Email: neuland@neulandlabs.com
Unit-1 : Survey No: 474, 347, 490/2, 488G & 489A, Bonthapally (V), Veerabhadraswamy Temple Road, Jinnaram (M), Medak Dist - 502313 AP, India, Tel : 08458-392724
Unit-2 : IDA, Pashamylaram, Isnapur Village, Patancheru (M), Medak Dist - 502 319 AP, India, Tel : 08455-302145



Neuland

Experience. Insight. Vision.

PART - II

Sl. No.	Particulars	Quarter Ended 31.12.2013 (Unaudited)	Quarter Ended 30.09.2013 (Unaudited)	Quarter Ended 31.12.2012 (Unaudited)	Nine Months Ended 31.12.2013 (Unaudited)	Nine Months Ended 31.12.2012 (Unaudited)	Year Ended 31.03.2013 (Audited)
A	PARTICULARS OF SHARE HOLDING						
1	Public Shareholding						
	(a) Number of Shares	3,817,199	3,817,199	3,817,199	3,817,199	3,817,199	3,817,199
	(b) Percentage of Shareholding	49.93%	49.93%	49.93%	49.93%	49.93%	49.93%
2	Promoters and Promoter Group Shareholding						
	(a) Pledged / Encumbered						
	-Number of Shares	200,000	200,000	200,000	200,000	200,000	200,000
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	5.22%	5.22%	5.22%	5.22%	5.22%	5.22%
	-Percentage of Shares (as a % of the total share capital of the Company)	2.62%	2.62%	2.62%	2.62%	2.62%	2.62%
	(b) Non-encumbered						
	-Number of Shares	3,627,779	3,627,779	3,627,779	3,627,779	3,627,779	3,627,779
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	94.78%	94.78%	94.78%	94.78%	94.78%	94.78%
	-Percentage of Shares (as a % of the total share capital of the Company)	47.45%	47.45%	47.45%	47.45%	47.45%	47.45%

B INVESTOR COMPLIANTS

Particulars	Quarter Ended 31.12.2013
Pending at the beginning of the quarter	0
Received during the quarter	7
Disposed off during the quarter	7
Remaining unresolved at the end of the quarter	0

NOTES:

- The above unaudited financial results which have been subjected to a limited review by statutory auditors, were reviewed by the Audit Committee at its meeting held on February 4, 2014, and approved and taken on record at the Board of Directors meeting held on February 5, 2014.
- EPS for the quarters and nine months is not annualised.
- The Company's operations are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Accounting Standard - AS 17 "Segment Reporting".
- The Board had on January 21, 2014, issued and allotted 10,700 fully paid up equity shares of a face value of ₹10 each, to eligible employees pursuant to exercise of stock options granted under Employee Stock Option Scheme, 2008.
- The Board of Directors of the Company at their meeting held on February 5, 2014 accorded consent to a rights issue of equity shares not exceeding ₹25 crores. The Board had also constituted a Rights issue committee to finalise the rights ratio, issue price, record date and other procedural modalities relating to the proposed rights issue.
- Previous quarter / year figures have been regrouped wherever necessary.

By Order of the Board
For Neuland Laboratories Limited

Dr. D.R. Rao
Chairman & Managing Director

Place: Hyderabad
Date: February 5, 2014

Neuland Laboratories Limited

K. S. AIYAR & CO

CHARTERED ACCOUNTANTS

F-7 Laxmi Mills
Shakti Mills Lane (Off Dr E Moses Rd)
Mahalaxmi Mumbai 400 011 India
Tel : 91 22 2493 2502 / 6655 1770
Fax : 91 22 6655 1774
Grams : VERIFY
www.KSAiyar.com
Mail@KSAiyar.com

To,
The Board of Directors,
Neuland Laboratories Limited
Sanali Info Park, 'A' Block, Ground Floor,
8-2-120/113, Rd No 2, Banjara Hills,
Hyderabad – 500 034

Re: Limited Review of the unaudited financial results for the quarter ended December 31, 2013.

1. Introduction

We have reviewed the accompanying statement of unaudited financial results of **Neuland Laboratories Limited** for the quarter ended December 31, 2013 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.


2. Scope of Review

We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3. Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K. S. Aiyar & Co.,
Chartered Accountants
Registration No. 100186W



Raghuvir M. Aiyar
Partner
Membership No: 38128

Place: Mumbai
Date: February 05, 2014

Offices also at
Chennai Kolkata Goa
Bangalore Coimbatore